Tuberkulose

Zusammenfassung

Die Tuberkulose gehört zu den bedeutendsten Ursachen für Morbidität und Mortalität weltweit. Die zunehmende Entwicklung multiresistenter Stämme von Mycobacterium tuberculosis, besonders in der WHO Region Europa, ist sehr besorgniserregend. In jüngster Zeit wurden bedeutende Fortschritte auf den Gebieten der Tuberkulose-Prävention, -Diagnostik und -Therapie, sowie im Management der multiresistenten Tuberkulose erzielt. Wissenschaftliche Höhepunkte der letzten Monate sind in dieser Kurzübersicht zusammengestellt.

Abstract

Tuberculosis ranges among the most important causes of morbidity and mortality worldwide. The emergence of drug-resistant strains of Mycobacterium tuberculosis, especially in the WHO Region Europe, is of serious concern. Recently, important advances have been achieved in the areas of tuberculosis prevention, diagnosis and treatment and in the management of patients with multidrug-resistant tuberculosis. Recent highlights are being presented in this mini-review.

Schlüsselwörter

IGRA - MDR-TB - Gesamt-Genomsequenzierung - persönliche Medizin - update

Keywords

IGRA - MDR-TB - personalized medicine - whole-genome sequencing

• Literatur

• 1 Lonnroth K, Migliori GB, Abubakar I et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952
• 2 Kaufmann SH, Lange C, Rao M et al. Progress in tuberculosis vaccine development and host-directed therapies – a state of the art review. Lancet Respir Med 2014; 2: 301-320
• 3 Sester M, van Crevel R, van Leth F et al. Numbers needed to treat to prevent tuberculosis. Eur Respir J 2015; (in press)
• 4 Lange C, van Leth F, Sester M. Viral load and risk of tuberculosis in HIV-infection. J Acquir Immune Defic Syndr 2015; (in press)
• 5 Olaru ID, Lange C, Sester M. Revisiting health care workers as a risk group for progression towards tuberculosis. Am J Respir Crit Care Med 2015; (in press)
• 6 Gutsfeld C, Olaru ID, Vollrath O et al. Attitudes about tuberculosis prevention in the elimination phase: a survey among physicians in Germany. PloS one 2014; 9: e112681
• 7 Sterling TR, Villarino ME, Borisov AS. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 2155-2166
• 8 Sanchez-Padilla E, Merker M, Beckert P, Jochims F, Dlamini T, Kahn P et al. Detection of drug-resistant tuberculosis by Xpert MTB / RIF in Swaziland. N Engl J Med 2015; 372: 1181-1182
• 9 Steingart KR, Schiller I, Horne DJ et al. Xpert(R) MTB / RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014; 1 CD009593
• 10 Denkinger CM, Schumacher SG, Boehme CC et al. Xpert MTB / RIF assay for the diagnosis of extrapulmonary tuberculosis: A systematic review and meta-analysis. Eur Respir J 2014; 44: 435-446
• 11 Chen JH, She KK, Kwong TC et al. Performance of the new automated Abbott RealTime MTB assay for rapid detection of Mycobacterium tuberculosis complex in respiratory specimens. Eur J Clin Microbiol Infect Dis 2015; 34: 1827-1832
• 12 Walker TM, Kohl TA, Omar SV et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 2015; DOI: 10.1016/S1473-3099(15)00062-6.
• 13 Gillespie SH, Crook AM, McHugh TD et al. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. N Engl J Med 2014; 371: 1577-1587
• 14 Jindani A, Harrison TS, Nunn AJ et al. High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. N Engl J Med 2014; 371: 1599-1608
• 15 Merle CS, Fielding K, Sow OB et al. A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis. N Engl J Med 2014; 371: 1588-1598
• 16 Ruslami R, Ganiem AR, Dian S et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013; 13: 27-35
• 17 Boeree MJ, Diacon AH, Dawson R et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 2015; 191: 1058-1065
• 18 Gunther G, van Leth F, Alexandru S et al. Multidrug-resistant tuberculosis in Europe, 2010–2011. Emerg Infect Dis 2015; 21: 409-416
• 19 Lange C, Abubakar I, Alffenaar JW et al. Management of patients with multidrug-resistant / extensively drug-resistant tuberculosis in Europe: A TBNET consensus statement. Eur Respir J 2014; 44: 23-63
• 20 Gunther G, Gomez GB, Lange C et al. Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey. Eur Respir J 2015; 45: 1081-1088
• 21 Diacon AH, Pym A, Grobusch MP et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732
• 22 European Centre for Disease Prevention and Control / WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe. 2015. Im Internet: http://ecdc.europa.eu/en/publications/Publications/tuberculosis-surveillance-monitoring-Europe-2015.pdf Letzter Zugriff: 2.9.2015
• 23 Sester M, van Leth F, Bruchfeld J et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 2014; 190: 1168-1176
• 24 Zellweger JP, Sotgiu G, Block M et al. Risk Assessment of Tuberculosis in Contacts by IFN-gamma Release Assays. A Tuberculosis Network European Trials Group Study. Am J Respir Crit Care Med 2015; 191: 1176-1184
• 25 Sloot R, Schim van der Loeff MF, Kouw PM, Borgdorff MW. Yield of tuberculosis contact investigations in Amsterdam: opportunities for improvement. Eur Respir J 2014; 44: 714-724
• 26 Brown AC, Bryant JM, Einer-Jensen K et al. Rapid Whole-Genome Sequencing of Mycobacterium tuberculosis Isolates Directly from Clinical Samples. J Clin Microbiol 2015; 53: 2230-2237